Novel Evidence-Based Systemic Lupus Erythematosus Responder Index

OBJECTIVE: To describe a new systemic lupus erythematosus (SLE) Responder Index (SRI) based on the belimumab phase II SLE trial and demonstrate its potential utility in SLE clinical trials. METHODS: Data from a 449-patient randomized, double-blind, placebo-controlled study of 3 doses of belimumab (1...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Furie, Richard A., Petri, Michelle A., Wallace, Daniel J., Ginzler, Ellen M., Merrill, Joan T., Stohl, William, Chatham, W. Winn, Strand, Vibeke, Weinstein, Arthur, Chevrier, Marc R., Zhong, John, Freimuth, William W.
Formato: Artigo
Idioma:Inglês
Publicado em: 2009
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2748175/
https://ncbi.nlm.nih.gov/pubmed/19714615
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.24698
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados